-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

Benzinga·04/17/2026 14:55:30
Listen to the news
HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $7 to $2.5.